New Lung Cancer Drug Works in Trial

Tuesday, 13 Aug 2013 12:06 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Eli Lilly and Co said its experimental lung cancer drug increased survival of patients in a late-stage trial, and the company plans to file for a U.S. marketing application before the end of 2014.
Lilly shares were up 4 percent in premarket trading.
The drug, necitumumab or IMC-11F8, was given to patients with advanced non-small cell lung cancer in combination with already-approved chemotherapy drug gemcitabine and cisplatin, and was compared with chemotherapy alone.
"If approved, necitumumab could be the first biologic therapy indicated to treat patients with squamous lung cancer," Richard Gaynor, Lilly's vice president for product development and medical affairs, said in a statement.
The company's stock closed at $54.05 on the New York Stock Exchange on Monday.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Ebola Survivor Praises Experimental Drug

Saturday, 30 Aug 2014 11:28 AM

A Liberian Ebola survivor who received an experimental drug urged the manufacturer to speed up its production and send i . . .

Experimental Heart Failure Drug Shows Promise

Saturday, 30 Aug 2014 11:17 AM

An experimental drug has been shown to be more effective than standard treatment at preventing deaths and hospitalizatio . . .

With Prostate Cancer, It Helps to Know the Enemy

Friday, 29 Aug 2014 16:47 PM

Prostate cancer patients lacking knowledge about the disease have difficulty making good treatment decisions. This can l . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved